Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials
When medically appropriate, we prescribe GLP-1s for conditions like cardiac and vascular disease, sleep apnea, kidney disease, type 2 diabetes and stroke risk
Specifically, GLP-1Rs on vagal afferent neurons have been shown to contribute to the incretin effects of GLP-1 shortly after a meal, gastric emptying, and glycemia (Krieger et al., 2015)
...and so much more
These numbers are higher than what you see with semaglutide or tirzepatide at comparable stages
A well-established part of how they work is slowing gastric emptying, so food stays in the stomach longer, and this is documented in the FDA prescribing information for these drugs